Dr Reddy’s launches generic Ciprodex in US market

Our Bureau Hyderabad | Updated on August 11, 2020

Dr Reddy’s Laboratories Ltd has launched Ciprofloxacin and Dexamethasone Otic Suspension in the US market.

The products are a therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3 per cent and dexamethasone 0.1 per cent) Otic Suspension, approved by the US Food and Drug Administration (USFDA).

“We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients,” Marc Kikuchi, Chief Executive Officer, North America Generics, Dr.Reddy’s Laboratories, said in a release.

The company was actively expanding the depth of its portfolio with its first otic suspension dosage form, he added.

The Ciprodex brand had US sales of approximately $453 million for the most recent 12 months ending in June, according to IQVIA Health.

Dr Reddy’s Ciprofloxacin 0.3 per cent and Dexamethasone 0.1 per cent Otic Suspension, USP, is available as 7.5 ml fill in a 10 ml bottle. Ciprodex is a trademark of Bayer AG.

Published on August 11, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like